HDAC3-Mediated Repression of the Nr4a Family Contributes to Age-Related Impairments in Long-Term Memory.
Kwapis JL, Alaghband Y, López AJ, Long JM, Li X, Shu G, Bodinayake KK, Matheos DP, Rapp PR, Wood MA
NR4A2 gene activity is reduced in aging brains, contributing to memory problems. Boosting NR4A2 or its close relative NR4A1 in the brain can improve memory in old animals, suggesting a potential treatment path for age-related cognitive decline.
- NR4A2 is essential for memory and declines with age
- HDAC3 blocks NR4A2 in old brains
- Increasing NR4A1 or NR4A2 improves memory in aged mice
- Targeting this pathway may help treat memory loss in aging
- This mechanism may apply to NR4A2-related disorders
Epigenetic regulation of immediate-early gene Nr4a2/Nurr1 in the medial habenula during reinstatement of cocaine-associated behavior.
López AJ, Hemstedt TJ, Jia Y, Hwang PH, Campbell RR, Kwapis JL, White AO, Chitnis O, Scarfone VM, Matheos DP, Lynch G, Wood MA
NR4A2 function in the medial habenula is essential for relapse-like behaviors in cocaine addiction, with HDAC3 regulating this process. Disrupting NR4A2 in this brain region prevents reinstatement of drug-seeking behavior.
- NR4A2 in the medial habenula controls relapse behaviors
- HDAC3 detachment from NR4A2 triggers relapse
- Blocking NR4A2 function stops reinstatement
- This pathway is a potential target for preventing relapse
Repeated bifenthrin exposure alters hippocampal Nurr-1/AChE and induces depression-like behavior in adult rats.
Gargouri B, Bouchard M, Saliba SW, Fetoui H, Fiebich BL
Repeated exposure to the insecticide bifenthrin harms the hippocampus in adult rats, reducing levels of Nurr-1 and acetylcholinesterase, disrupting brain signaling, and causing depression-like behavior. These changes mirror some features seen in human neurodevelopmental disorders.
- Bifenthrin reduces Nurr-1 and acetylcholinesterase in the hippocampus
- Exposure leads to depression-like behavior in rats
- Brain signaling and enzyme activity are disrupted
- Apoptosis increases in hippocampal cells
- Findings may inform NR4A2-related syndrome mechanisms
Altered Expression Levels of MicroRNA-132 and Nurr1 in Peripheral Blood of Parkinson's Disease: Potential Disease Biomarkers.
Yang Z, Li T, Li S, Wei M, Qi H, Shen B, Chang RC, Le W, Piao F
People with Parkinson's disease have higher levels of a microRNA called miR-132 and lower levels of a protective protein called Nurr1 in their blood. These changes are linked to disease severity and may help diagnose Parkinson's and track how it progresses.
- miR-132 is elevated in Parkinson's blood
- Nurr1 is reduced in Parkinson's blood
- High miR-132 and low Nurr1 correlate with disease severity
- This pair may serve as a blood-based biomarker
- Findings are from human patients, not just animals
Covalent Modification and Regulation of the Nuclear Receptor Nurr1 by a Dopamine Metabolite.
Bruning JM, Wang Y, Oltrabella F, Tian B, Kholodar SA, Liu H, Bhattacharya P, Guo S, Holton JM, Fletterick RJ, Jacobson MP, England PM
A dopamine breakdown product called DHI binds to and activates Nurr1, a protein critical for dopamine neuron health. This interaction happens through a unique chemical bond and boosts Nurr1's ability to regulate genes involved in dopamine balance, offering a potential path for treating Parkinson's disease.
- DHI, a dopamine metabolite, activates Nurr1
- DHI binds covalently to Cys566 in Nurr1
- This binding boosts Nurr1's gene-regulating activity
- Activation occurs in a non-canonical pocket
- Findings may lead to new Parkinson's treatments
Molecular and genetic characterization of partial masculinization in embryonic ovaries grafted into male nude mice.
Miura K, Harikae K, Nakaguchi M, Imaimatsu K, Hiramatsu R, Tomita A, Hirate Y, Kanai-Azuma M, Kurohmaru M, Ogura A, Kanai Y
Testosterone from male host mice causes fetal ovaries to partially change into testis-like tissue, turning on male genes and turning off female genes in a step-by-step way over time. This shows how external hormones can override normal ovarian development, even in genetically normal ovaries.
- Male testosterone triggers ovarian cells to act like testis cells
- Female genes turn off early; male genes turn on later
- This happens even in normal ovaries without genetic changes
- The process is gradual and time-dependent
- Could help explain hormone-driven sex development changes
Minocycline Protects against Rotenone-Induced Neurotoxicity Correlating with Upregulation of Nurr1 in a Parkinson's Disease Rat Model.
Sun C, Wang Y, Mo M, Song C, Wang X, Chen S, Liu Y
Minocycline reduced brain damage and improved movement in rats with Parkinson's-like symptoms by boosting levels of Nurr1, a protein linked to nerve cell survival. This suggests minocycline may protect brain cells in conditions involving Nurr1 deficiency.
- Minocycline improved movement in Parkinson's-like rats
- It increased Nurr1 levels in brain cells
- It reduced harmful brain chemicals like ROS and NO
- Nurr1 upregulation may be key to protection
- Findings suggest minocycline could help in NR4A2-related disorders
Hydroxychloroquine antiparkinsonian potential: Nurr1 modulation versus autophagy inhibition.
Hedya SA, Safar MM, Bahgat AK
Hydroxychloroquine improved motor symptoms in a rat model of Parkinson's disease by boosting Nurr1, a protein linked to NR4A2-related syndrome, though it also disrupted autophagy and increased cell death. The benefits from Nurr1 activation appear to outweigh the risks in this model.
- Hydroxychloroquine boosts Nurr1, a key protein in NR4A2-related syndrome
- It improved movement and coordination in a Parkinson's rat model
- The drug also blocked autophagy and increased cell death
- Nurr1 activation may be protective despite other harmful effects
A Nurr1 agonist amodiaquine attenuates inflammatory events and neurological deficits in a mouse model of intracerebral hemorrhage.
Kinoshita K, Matsumoto K, Kurauchi Y, Hisatsune A, Seki T, Katsuki H
A drug called amodiaquine, which activates the Nurr1 protein (NR4A2), reduces brain inflammation and improves movement recovery in mice after a stroke caused by brain bleeding. This suggests that targeting Nurr1 could be a promising treatment for brain injury after hemorrhage.
- Nurr1 is active in brain immune cells after brain bleeding
- Amodiaquine, a Nurr1 activator, reduces brain inflammation
- Amodiaquine improves motor recovery in mice
- Targeting Nurr1 may help treat brain hemorrhage
- Results support Nurr1 as a potential therapy target
Genetic Elimination of Connective Tissue Growth Factor in the Forebrain Affects Subplate Neurons in the Cortex and Oligodendrocytes in the Underlying White Matter.
Yu IS, Chang HC, Chen KC, Lu YL, Shy HT, Chen CY, Lee KY, Lee LJ
Removing CTGF in the mouse forebrain disrupts the development and structure of subplate neurons and affects oligodendrocyte maturation and myelin thickness over time, suggesting CTGF helps guide early brain wiring and white matter formation.
- CTGF loss increases subplate neuron density and reduces their branching
- Mature oligodendrocytes increase in white matter beneath the cortex
- Myelin sheath thickness decreases in middle-aged mice, not young adults
- Subplate neurons likely release CTGF to influence nearby glial cells
- Findings highlight CTGF's role in early brain circuit development
Decreased Steroid Hormone Receptor NR4A2 Expression in Kawasaki Disease Before IVIG Treatment.
Huang YH, Chen KD, Lo MH, Cai XY, Kuo HC
NR4A2 levels are lower in children with Kawasaki disease before IVIG treatment, which may explain why steroids are less effective at this stage. After IVIG, NR4A2 levels rise, suggesting steroids could then help reduce inflammation. This finding may guide when to use steroids alongside IVIG.
- NR4A2 is reduced before IVIG treatment
- NR4A2 increases after IVIG
- Low NR4A2 may block steroid effectiveness early
- Steroids may work better after IVIG
- Timing of steroid use could be optimized
Structural insights into ligand-binding pocket formation in Nurr1 by molecular dynamics simulations.
Windshügel B
Nurr1, a protein linked to Parkinson's disease, can temporarily form a pocket that binds the potential treatment compound DHA, even though this pocket isn't visible in static structures. This dynamic behavior suggests that drugs could be designed to stabilize this pocket and activate Nurr1 for therapy.
- Nurr1 can form a temporary pocket to bind DHA
- Only small changes in Nurr1's shape are needed for this pocket to form
- This dynamic pocket could be targeted by new drugs
- Findings support designing better Nurr1 activators
Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease.
Lesuisse D, Malanda A, Peyronel JF, Evanno Y, Lardenois P, De-Peretti D, Abécassis PY, Barnéoud P, Brunel P, Burgevin MC, Cegarra C, Auger F, Dommergue A, Lafon C, Even L, Tsi J, Luc TPH, Almario A, Olivier A, Castel MN, Taupin V, Rooney T, Vigé X
A new drug candidate that activates the NURR1 protein shows strong potential for protecting brain cells and reducing inflammation in models of Parkinson's disease, advancing toward possible human treatment.
- New drug activates NURR1, a key protein in Parkinson's
- Shows brain protection and anti-inflammatory effects
- Optimized for safety and potency in lab models
- Represents a promising step toward therapy
The orphan nuclear receptor Nor1/Nr4a3 is a negative regulator of β-cell mass.
Close AF, Dadheech N, Villela BS, Rouillard C, Buteau J
Nor1, a gene related to NR4A2, reduces the number of insulin-producing cells in the pancreas and promotes their death, especially under stress from inflammation or high blood sugar. Blocking Nor1 protects these cells, suggesting it could be a target for new diabetes treatments.
- Nor1 reduces insulin-producing cell mass
- Nor1 increases when cells face stress from inflammation or high glucose
- Blocking Nor1 protects pancreatic cells from death
- Nor1 is higher in people with type 2 diabetes
- Targeting Nor1 may help preserve insulin production
Molecular Insights into NR4A2(Nurr1): an Emerging Target for Neuroprotective Therapy Against Neuroinflammation and Neuronal Cell Death.
Jakaria M, Haque ME, Cho DY, Azam S, Kim IS, Choi DK
NR4A2 is a key protein that protects brain cells, especially dopamine-producing neurons, by reducing inflammation and preventing cell death. Low levels of NR4A2 are linked to Parkinson's, Alzheimer's, and other brain diseases, and boosting it may help treat these conditions.
- NR4A2 protects dopamine neurons from damage
- Low NR4A2 levels are seen in Parkinson's and Alzheimer's
- Activating NR4A2 may reduce brain inflammation
- MicroRNAs can control NR4A2 levels
- NR4A2 is a promising target for new brain disease treatments
Global Gene Knockout of Kcnip3 Enhances Pain Sensitivity and Exacerbates Negative Emotions in Rats.
Guo YP, Zhi YR, Liu TT, Wang Y, Zhang Y
Rats without the Kcnip3 gene show increased pain sensitivity and worse anxiety and depression-like behaviors, likely due to changes in brain genes involved in dopamine signaling, including Nr4a2.
- Kcnip3 knockout rats feel more pain and show stronger negative emotions
- Nr4a2 and other dopamine-related genes are upregulated in the brain
- Kcnip3 may help regulate pain and mood through gene control
- Changes in brain gene activity suggest a role in central pain processing
- Findings point to potential pathways for treating pain and emotional issues
Dysregulation of Dopaminergic Regulatory Factors TH, Nurr1, and Pitx3 in the Ventral Tegmental Area Associated with Neuronal Injury Induced by Chronic Morphine Dependence.
Shi W, Zhang Y, Zhao G, Wang S, Zhang G, Ma C, Cong B, Li Y
Chronic morphine use damages dopamine-producing neurons in the brain's reward center, leading to reduced levels of key proteins (TH, Nurr1, Pitx3) that protect and maintain these neurons. This disruption is linked to visible neuron damage and may explain long-term brain changes in addiction.
- Morphine harms dopamine neurons in the brain's reward center
- Critical neuron-protecting proteins drop during long-term morphine use
- Neuron damage correlates with loss of TH, Nurr1, and Pitx3
- These changes may underlie addiction-related brain changes
- Findings highlight potential targets for protecting brain cells
[The mechanism underlying Gingko biloba extract alleviating acrylamide-induced inflammatory response of mouse microglia].
Wang C, Yang Z, He X
Ginkgo biloba extract reduces brain inflammation in mouse cells by blocking a key inflammatory pathway and boosting a protective protein complex that suppresses harmful gene activity.
- Ginkgo biloba extract reduces brain cell inflammation
- It works by blocking NF-κB, a major inflammation trigger
- It boosts Nurr1-CoREST, a natural suppressor of inflammation
- This suggests a potential way to calm overactive brain immune cells
- Findings may inform treatments for neuroinflammatory conditions
Subcellular Localization of NR4A2 Orphan Nuclear Receptor Expression in Human and Mouse Synovial Joint Tissue.
Smyth A, Gogarty M, Crean D, Murphy EP
NR4A2 is found in specific cells within joint tissues of people and mice with inflammatory arthritis, suggesting it plays a role in joint inflammation. Understanding where NR4A2 is located helps clarify its function in disease and may guide future treatments.
- NR4A2 is present in inflamed joint tissues in humans and mice
- Its location varies by cell type, affecting its role in inflammation
- This localization may influence how inflammation develops and resolves
- Findings could help target NR4A2 for new therapies
Potential effects and molecular mechanisms of melatonin on the dopaminergic neuronal differentiation of human amniotic fluid mesenchymal stem cells.
Phonchai R, Phermthai T, Kitiyanant N, Suwanjang W, Kotchabhakdi N, Chetsawang B
Melatonin helps human stem cells from amniotic fluid turn into dopamine-producing brain cells, likely by activating key signaling pathways through melatonin receptors and other mechanisms. This suggests melatonin could support therapies for conditions involving dopamine loss, such as NR4A2-related syndrome.
- Melatonin boosts formation of dopamine neurons from stem cells
- It works through ERK and CaMKII signaling pathways
- Effects involve both melatonin receptor-dependent and independent routes
- No harm to stem cell survival or growth
- Potential for improving cell-based treatments for dopamine disorders
Study of the NR4A family gene expression in patients with multiple sclerosis treated with Fingolimod.
Montarolo F, Perga S, Martire S, Brescia F, Caldano M, Lo Re M, Panzica G, Bertolotto A
Fingolimod treatment in multiple sclerosis patients increases NR4A2 levels in blood, bringing them closer to normal levels seen in healthy people. This suggests the drug may help reverse a key biological deficit linked to the disease.
- Fingolimod raises NR4A2 levels in MS patients
- NR4A2 is low in untreated MS patients
- Higher NR4A2 correlates with less severe disease
- Fingolimod may correct a core NR4A2 deficit
- NR4A2 could be a marker of treatment response
Nurr1 (NR4A2) regulates Alzheimer's disease-related pathogenesis and cognitive function in the 5XFAD mouse model.
Moon M, Jung ES, Jeon SG, Cha MY, Jang Y, Kim W, Lopes C, Mook-Jung I, Kim KS
Nurr1, a gene linked to Parkinson's disease, also plays a key role in Alzheimer's disease pathology. Boosting Nurr1 activity in mice with Alzheimer's-like symptoms reduces amyloid plaques, brain inflammation, and cognitive decline, suggesting it could be a promising treatment target.
- Nurr1 is active in brain cells affected by Alzheimer's
- Increasing Nurr1 reduces amyloid plaques and brain inflammation
- A drug that activates Nurr1 improves memory in Alzheimer's mice
- Nurr1 may be a new target for treating Alzheimer's disease
- These findings are based on both mouse models and human brain tissue
Genome sequencing identifies multiple deleterious variants in autism patients with more severe phenotypes.
Guo H, Duyzend MH, Coe BP, Baker C, Hoekzema K, Gerdts J, Turner TN, Zody MC, Beighley JS, Murali SC, Nelson BJ, University of Washington Center for Mendelian Genomics, Bamshad MJ, Nickerson DA, Bernier RA, Eichler EE
Genome sequencing found that children with autism and more severe symptoms often have multiple harmful genetic variants, including rare changes in the NR4A2 gene, which may explain why their condition is more severe. Having more than one risk variant is linked to lower cognitive ability.
- Multiple harmful variants increase autism severity
- NR4A2 has a de novo frameshift variant linked to autism
- Children with more than one risk variant show lower cognitive ability
- No pathogenic variants were passed to all affected family members
- Genome sequencing improves autism diagnosis and gene discovery
Alterations of NURR1 and Cytokines in the Peripheral Blood Mononuclear Cells: Combined Biomarkers for Parkinson's Disease.
Li T, Yang Z, Li S, Cheng C, Shen B, Le W
People with Parkinson's disease have lower levels of the NURR1 protein and higher levels of inflammatory cytokines in their blood cells, and combining these measurements improves the accuracy of diagnosing Parkinson's. This suggests NURR1 plays a role in brain inflammation linked to the disease.
- NURR1 levels are reduced in Parkinson's blood cells
- Inflammatory cytokines are elevated in Parkinson's
- Low NURR1 links to high inflammation
- Combining NURR1 and cytokines improves diagnosis
- Blood tests may help detect Parkinson's earlier
Differential expression of a stress-regulated gene Nr4a2 characterizes early- and late-born hippocampal granule cells.
Imura T, Kobayashi Y, Suzutani K, Ichikawa-Tomikawa N, Chiba H
Early-born and late-born hippocampal neurons differ in location, gene expression, and response to stress, with the Nr4a2 gene playing a key role in how these cells react to stress. Chronic stress reduces the number of late-born neurons, which may affect brain function over time.
- Early-born neurons are in the outer layer, late-born in the inner layer
- Nr4a2 is highly active in early-born neurons and responds to stress
- Chronic stress lowers Nr4a2 and reduces late-born neuron survival
- Stress affects neuron development and maintenance in the hippocampus
- This may impact learning, memory, and mental health over time
Defining a Canonical Ligand-Binding Pocket in the Orphan Nuclear Receptor Nurr1.
de Vera IMS, Munoz-Tello P, Zheng J, Dharmarajan V, Marciano DP, Matta-Camacho E, Giri PK, Shang J, Hughes TS, Rance M, Griffin PR, Kojetin DJ
Nurr1, a protein linked to Parkinson's disease and schizophrenia, has a flexible binding site that can open up to bind fatty acids, suggesting it may be targetable by drugs. This challenges the idea that Nurr1 lacks a functional ligand-binding pocket and opens new paths for developing treatments.
- Nurr1's binding site is dynamic and can open to bind molecules
- It can bind unsaturated fatty acids, suggesting natural ligands exist
- The flexible pocket may be druggable for treating Nurr1-related diseases
- Findings support developing new therapies for Parkinson's and schizophrenia
Dbx1-Derived Pyramidal Neurons Are Generated Locally in the Developing Murine Neocortex.
Rueda-Alaña E, Martínez-Garay I, Encinas JM, Molnár Z, García-Moreno F
Pyramidal neurons previously thought to come from the ventral pallium are actually generated locally in the dorsal neocortex during mouse development, challenging earlier ideas about their origin and migration.
- Dbx1-derived pyramidal neurons form in the dorsal neocortex, not the ventral pallium.
- No tangential migration from ventral pallium to neocortex was observed.
- These neurons are born locally in the dorsal pallial neuroepithelium.
- This finding revises the developmental origin of a transient cortical neuron population.
- Implications for understanding cortical circuit formation and neurodevelopmental disorders.
Image-guided phenotyping of ovariectomized mice: altered functional connectivity, cognition, myelination, and dopaminergic functionality.
Anckaerts C, van Gastel J, Leysen V, Hinz R, Azmi A, Simoens P, Shah D, Kara F, Langbeen A, Bols P, Laloux C, Prevot V, Verhoye M, Maudsley S, Van der Linden A
Ovariectomy in mice disrupts brain connectivity, cognition, and dopamine function, with changes in proteins linked to neurodevelopment, aging, and myelination. These findings highlight how hormonal imbalance affects brain health and may inform treatments for conditions involving dopamine signaling.
- Hormonal disruption harms brain connectivity and thinking skills
- Dopamine system is impaired, including NR4A2 and DRD3
- Myelin and nerve growth are affected
- Brain changes mirror aging and neurodegeneration
- Imaging can track these brain changes in real time
Phenotypic Reprogramming of Striatal Neurons into Dopaminergic Neuron-like Cells in the Adult Mouse Brain.
Niu W, Zang T, Wang LL, Zou Y, Zhang CL
Adult brain cells in mice can be reprogrammed into dopamine-producing cells, a process that may offer new treatments for neurological disorders like Parkinson's disease. This reprogramming uses specific genes and a drug, and the new cells act like real dopamine neurons.
- Adult brain cells can become dopamine neurons
- Reprogramming uses NURR1 and other key genes
- New cells behave like natural dopamine neurons
- Potential therapy for Parkinson's and similar conditions
- Uses a drug (valproic acid) and gene factors
Illuminated night alters hippocampal gene expressions and induces depressive-like responses in diurnal corvids.
Taufique SKT, Prabhat A, Kumar V
Exposure to dim light at night disrupts sleep, reduces brain health, and causes depression-like behaviors in crows by altering gene activity in the hippocampus, including the NR4A2 gene, which is linked to brain function and mood. These changes involve suppressed neurogenesis and epigenetic modifications that may affect how genes are turned on or off.
- Dim light at night harms brain health and behavior in diurnal birds
- NR4A2 gene expression is reduced under light pollution
- Epigenetic changes may affect brain gene regulation
- Sleep and mood are disrupted by artificial nighttime light
- These effects reverse when returning to total darkness
Nurr1 exacerbates cerebral ischemia-reperfusion injury via modulating YAP-INF2-mitochondrial fission pathways.
Zhang Z, Yu J
Nurr1 worsens brain damage after stroke by triggering excessive mitochondrial division, leading to neuron death. Blocking Nurr1 or its downstream pathway preserves mitochondrial function and protects brain cells.
- Nurr1 increases brain damage after stroke
- Nurr1 triggers harmful mitochondrial division
- Blocking Nurr1 protects brain cells
- The YAP-INF2 pathway is key to this damage
- Targeting this pathway may reduce stroke injury
Epinephrine Released During Traumatic Events May Strengthen Contextual Fear Memory Through Increased Hippocampus mRNA Expression of Nr4a Transcription Factors.
Oliveira A, Martinho R, Serrão P, Moreira-Rodrigues M
Epinephrine released during stressful events strengthens fear memories by increasing expression of Nr4a2 and related genes in the hippocampus, a brain region involved in memory. This process depends on beta-2 adrenergic receptors and may involve blood glucose as a messenger to the brain.
- Epinephrine boosts fear memory formation via beta-2 receptors
- Nr4a2 gene expression rises in the hippocampus after stress
- Blocking beta-2 receptors reduces fear memory and glucose response
- Blood glucose may link stress hormones to memory changes
- This pathway could influence long-term memory consolidation
Progression of myocardial ischemia leads to unique changes in immediate-early gene expression in the spinal cord dorsal horn.
Saddic LA, Howard-Quijano K, Kipke J, Kubo Y, Dale EA, Hoover D, Shivkumar K, Eghbali M, Mahajan A
This study found that gene activity in the spinal cord changes as heart damage progresses over time, with specific genes linked to nerve signaling and stress responses becoming active. These changes may explain how the body's initial protective response to heart injury eventually turns harmful, contributing to dangerous heart rhythms and heart failure.
- Spinal cord gene activity shifts during heart injury progression
- NR4A2 and other immediate-early genes stay active in chronic injury
- These changes may drive harmful long-term nervous system responses
- Gene patterns link to stress, immune response, and cell death
- Findings could inform treatments targeting nerve signaling after heart attacks
Sevoflurane anesthesia represses neurogenesis of hippocampus neural stem cells via regulating microRNA-183-mediated NR4A2 in newborn rats.
Shao CZ, Xia KP
Exposure to sevoflurane anesthesia in newborn rats reduces the growth and development of brain cells in the hippocampus by increasing a molecule called miR-183, which suppresses NR4A2, a gene important for brain health. This mechanism may explain why anesthesia could affect brain development in young children.
- Sevoflurane reduces brain cell growth in newborns
- miR-183 increases after anesthesia and blocks NR4A2
- NR4A2 is critical for healthy brain development
- This pathway may affect neurodevelopment in infants
- Findings suggest caution with anesthesia in young children
Axin-2 knockdown promote mitochondrial biogenesis and dopaminergic neurogenesis by regulating Wnt/β-catenin signaling in rat model of Parkinson's disease.
Singh S, Mishra A, Mohanbhai SJ, Tiwari V, Chaturvedi RK, Khurana S, Shukla S
Blocking Axin-2 boosts Wnt signaling, improves mitochondrial health, and increases the birth of dopamine-producing neurons in a rat model of Parkinson’s disease, suggesting a potential strategy to protect and regenerate these critical brain cells.
- Reducing Axin-2 enhances Wnt signaling in dopamine neurons
- Improved mitochondrial function and reduced cell death
- Increased generation of new dopamine neurons
- Activation of key genes needed for dopamine neuron development
- Potential pathway for regenerative therapies in Parkinson’s
Lethal Factor Domain-Mediated Delivery of Nurr1 Transcription Factor Enhances Tyrosine Hydroxylase Activity and Protects from Neurotoxin-Induced Degeneration of Dopaminergic Cells.
Paliga D, Raudzus F, Leppla SH, Heumann R, Neumann S
Delivering the Nurr1 protein directly into dopaminergic cells boosts dopamine production and protects these cells from damage, suggesting a potential new therapy for conditions like NR4A2-related syndrome and Parkinson’s disease.
- Nurr1 delivery increases dopamine-making enzyme levels
- Protected brain cells from toxin damage in lab models
- Uses a safe delivery method to get Nurr1 into cells
- Supports protein therapy as a possible treatment path
- Relevant to NR4A2-related disorders and Parkinson’s